Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study-Reference-Cited by-同舟云学术

Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study

Published:2022-12-28 Issue:1 Volume:26 Page:43-50
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Hess Lisa M.¹^ORCID,Michael Diane¹,Krein Peter M.²,Marquart Tyler²,Sireci Anthony N.²

Affiliation:

1. Eli Lilly and Company, Indianapolis, IN, USA

2. LOXO@Lilly, Indianapolis, IN, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2154479

Reference29 articles.

1. Cancer statistics, 2022

2. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

3. NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer, version 3.2022 [cited 2022 Jun 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

4. NCCN clinical practice guidelines in oncology (NCCN guidelines) thyroid carcinoma version 2.2022 [cited 2022 Jun 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empowering effective biomarker-driven precision oncology: A call to action;European Journal of Cancer;2024-09

2. Cancer genetics and treatment rift: Perspectives for coping challenges in low and middle-income countries;Current Problems in Cancer;2024-06

3. Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study;JTO Clinical and Research Reports;2024-03

4. Empowering Effective Biomarker-Driven Precision Oncology a Call to Action;2024